C84.Z7 Other mature T/NK-cell lymphomas, spleen

Name of the Condition

• Other mature T/NK-cell lymphomas, spleen (ICD-10 Code: C84.Z7).

Summary

This condition represents a group of uncommon non-Hodgkin lymphomas that originate from mature T-lymphocytes or natural killer (NK) cells, specifically involving the spleen. These lymphomas are characterized by diverse clinical presentations and may affect other tissues, though the primary site is limited to the spleen.

Causes

The exact cause is often unknown but may involve genetic mutations in T-cells or NK-cells, leading to uncontrolled growth. Viral infections such as Epstein-Barr virus (EBV) or human T-cell leukemia virus (HTLV) have been associated with some subtypes, though their role varies.

Risk Factors

• Age: Typically affects adults, with higher prevalence in older age groups.
• Immunosuppression: Conditions or treatments that weaken the immune system may increase risk.
• Viral exposures: Prior infection with EBV, HTLV, or other oncogenic viruses.
• Ethnicity: Some subtypes show higher incidence in specific populations.
• Genetic predispositions: Family history of lymphoma or related disorders.

Symptoms

• Enlarged spleen (splenomegaly) causing abdominal discomfort or fullness.
• Fever, night sweats, and unexplained weight loss (B symptoms).
• Fatigue, loss of appetite, and general malaise.
• Anemia or thrombocytopenia due to spleen involvement.

Diagnosis

Diagnosis typically involves a combination of clinical evaluation, imaging studies (e.g., CT or MRI of the abdomen), and tissue biopsy of the spleen or affected lymph nodes. Laboratory tests, including complete blood counts and flow cytometry, may help identify abnormal T/NK-cell populations. Staging procedures assess the extent of disease.

Treatment Options

Treatment depends on the subtype, stage, and patient health. Options may include chemotherapy, immunotherapy (e.g., monoclonal antibodies), radiation therapy (for localized disease), or splenectomy (surgical removal of the spleen). Clinical trials or targeted therapies may be considered for specific subtypes.

Prognosis and Follow-Up

Prognosis varies by subtype and stage at diagnosis. Regular follow-up with imaging and blood tests is essential to monitor for recurrence or progression. Long-term surveillance helps manage potential late effects of treatment.

Complications

• Splenic rupture or severe pain due to enlargement.
• Cytopenias (low blood cell counts) from bone marrow involvement.
• Increased risk of infections, especially after splenectomy.
• Transformation to more aggressive lymphoma subtypes in rare cases.

Lifestyle & Prevention

• Maintain a balanced diet and regular exercise to support overall health.
• Avoid known carcinogens and practice good hygiene to reduce infection risk.
• Stay up-to-date with vaccinations, particularly after splenectomy.
• Limit alcohol and avoid smoking to support immune function.

When to Seek Professional Help

Seek medical attention for persistent abdominal pain, unexplained weight loss, fever, or fatigue. Prompt evaluation is critical if splenomegaly is suspected or if symptoms worsen.

Tips for Medical Coders

Use C84.Z7 for cases where the primary site of other mature T/NK-cell lymphoma is the spleen. Document the specific subtype (if known) and confirm the spleen as the primary site to ensure accurate coding. Avoid using this code for lymphomas with unspecified or multiple sites; instead, use the appropriate site-specific code.